A Phase 2 interventional study of Ibudilast and Placebo in Pneumonia, Viral, sponsored by MediciNova. Completed at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-10-30.
Sponsored by MediciNova · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,860 studies in COVID-19 with a site in United States, this one is the 925th largest by enrollment of the 1,322 interventional ones that give a count, is one of 504 that started in 2021, is one of 350 in phase 2, and was the 434th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–75
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,860 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 482 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 504 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 92 across the 1,322 interventional studies, 300 across the 521 observational. Of the 1,415 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,860 have an industry lead sponsor. The 10 most frequent:
MediciNova is the lead sponsor of 17 studies on the registry; none are open to participants now.
MediciNova has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
84 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-12 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 84 to your calendar (.ics) → With an account.
Among the 1,860 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate the effects of Ibudilast (MN-166) versus placebo in hospitalized patients infected with COVID-19 at risk for developing acute respiratory distress syndrome (ARDS) receiving standard of care (including anticoagulation therapy) by measuring the following outcomes: 1) the need for oxygen therapy at Days 7, 14, and 28, 2) clinical status as measured by the National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale at Days 7, 14, and 28, and 3) safety (as measured by incidence of adverse events and clinical laboratory findings) and tolerability of Ibudilast.
This is a randomized (1:1) double-blind, placebo-controlled, parallel-group study evaluating the efficacy of Ibudilast to prevent ARDS in hospitalized patients infected with COVID-19 who are at risk for developing ARDS. The study will consist of a Screening Phase, Double-Blind Treatment Phase, and Follow-up Phase. Following the Screening Phase, if the participant meets eligibility criteria, they will be randomly assigned to Ibudilast or matching placebo. Participants will receive Ibudilast 100 mg/d (50 mg twice a day) or placebo every day for 7 days. Upon completion of the 7-day Treatment Phase, subject will be followed-up at Day 14 and at Day 28. Participants discharged prior to Day 7 will be given the remainder of their study medication (Ibudilast or placebo) to be taken at home twice daily until Day 7 and will be given a pulse oximeter to measure their oxygen levels once daily until Day 14.
The following screening assessments will be performed upon signing the Informed Consent Form (ICF): inclusion/exclusion criteria review, physical exam, vital signs and oxygen use, clinical status using the NIAID ordinal scale, 12-lead ECG, blood collection for plasma biomarkers. A complete blood count (CBC), comprehensive metabolic panel (CMP), D-dimer and coagulation tests will also be drawn. A serum pregnancy test will be given to pre-menopausal female participants. Concomitant medications taken within the last 7 days prior to study drug administration will be recorded.
During the Treatment Phase, hospitalized participants will be treated with Ibudilast or placebo for a 7-day period plus standard of care and anticoagulation therapy. During the Treatment Phase, participants will undergo study-related procedures including physical exam, ECG, oxygen use assessment, biomarkers and pharmacokinetic sample draws, CBC, CMP, D-dimer blood collection, clinical status using the NIAID scale, and information on adverse events and concomitant medications will be recorded.
On Study Day 14, conduct physical examination, clinical status, vital signs and oxygen use, ECG, CBC, CMP, D-dimer, and coagulation tests, biomarkers, AE and concomitant medications review. On Day 28, participant's clinical status and survival status will be recorded.
If the participant is discharged before Day 7, they will be given the remainder of their study drug to take at home for up to 7 days, and the Sponsor will supply a pulse oximeter to participants to measure their oxygen levels once daily until Day 14.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
This study's enrollment of 34 is below the median of 102 across 4,369 interventional studies indexed under COVID-19.
Browse COVID-19 studies →MediciNova is the lead sponsor of 17 studies on the registry; none are open to participants now.
Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pneumonia, Viral. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ibudilast
Drug: Placebo
50 mg (5 x 10 mg capsules) twice daily for 7 days
Also known as: MN-166
0 mg (5 matching capsules) twice daily for 7 days
Number of Participants Free From Respiratory Failure at Day 7
Participants were considered "responders" if they did not meet the need for supplemental oxygen requirements (invasive mechanical ventilation, non-invasive ventilation, high-flow oxygen, or ECMO, CPAP, BiPAP, nasal cannula) at the end of the 7-day double-blind treatment.
Time frame: Day 7
Number of Participants With at Least a 1-point Improvement in Clinical Status on Day 7
Number (percentage) of participants with at least a 1-point improvement in clinical status on Day 7. Clinical status is measured by the National Institute of Allergy and Infectious Disease (NIAID) 8-Point Ordinal Scale: 1=Not hospitalized, no limitations on activities; 2=Not hospitalized, limitation on activities and/or requiring home oxygen; 3=Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4=Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) 5=Hospitalized, Hospitalized, requiring supplemental oxygen; 6=Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7=Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8=Death.
Time frame: Day 7
Number of Participants Receiving Mechanical Ventilation or Intubation
Number (percentage) of participants receiving mechanical ventilation or intubation after starting study drug.
Time frame: Days 7, 14, and 28
All-cause Mortality
Number of reported participant deaths
Time frame: Day 1 to Day 60
Number of Participants Discharged From Hospital at Days 7, 14, and 28
Number (percentage) of participants discharged from hospital at Days 7, 14, and 28
Time frame: Days 7, 14, and 28
| Milestone | Ibudilast (MN-166) | Placebo |
|---|---|---|
| Started | 17 | 17 |
| Completed | 15 | 15 |
| Not completed | 2 | 2 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Other | 2 | 0 |
Participants were considered "responders" if they did not meet the need for supplemental oxygen requirements (invasive mechanical ventilation, non-invasive ventilation, high-flow oxygen, or ECMO, CPAP, BiPAP, nasal cannula) at the end of the 7-day double-blind treatment.
| Participants | Ibudilast (MN-166) | Placebo |
|---|---|---|
| Number of Participants Free From Respiratory Failure at Day 7 | 12 | 6 |
Number (percentage) of participants with at least a 1-point improvement in clinical status on Day 7. Clinical status is measured by the National Institute of Allergy and Infectious Disease (NIAID) 8-Point Ordinal Scale: 1=Not hospitalized, no limitations on activities; 2=Not hospitalized, limitation on activities and/or requiring home oxygen; 3=Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4=Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) 5=Hospitalized, Hospitalized, requiring supplemental oxygen; 6=Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7=Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8=Death.
| Participants | Ibudilast (MN-166) | Placebo |
|---|---|---|
| Number of Participants With at Least a 1-point Improvement in Clinical Status on Day 7 | 12 | 8 |
Number (percentage) of participants receiving mechanical ventilation or intubation after starting study drug.
| Participants | Ibudilast (MN-166) | Placebo |
|---|---|---|
| Day 7 | 1 | 3 |
| Day 14 | 1 | 2 |
| Day 28 | 1 | 1 |
Number of reported participant deaths
| Participants | Ibudilast (MN-166) | Placebo |
|---|---|---|
| All-cause Mortality | 0 | 2 |
Number (percentage) of participants discharged from hospital at Days 7, 14, and 28
| Participants | Ibudilast (MN-166) | Placebo |
|---|---|---|
| Day 7 | 11 | 5 |
| Day 14 | 13 | 11 |
| Day 28 | 13 | 14 |
Collected over Adverse events occurring from the time of the first dose through 7 days after the last dose of MN-166 were recorded.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MN-166 (Ibudilast) | 0/17 (0%) | 5/17 (29.4%) | 13/17 (76.5%) |
| Placebo | 2/17 (11.8%) | 14/17 (82.4%) | 14/27 (51.9%) |
| Event | MN-166 (Ibudilast) | Placebo |
|---|---|---|
| Acute Kidney InjuryRenal and urinary disorders | 0/17 | 3/17 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/17 | 3/17 |
| ConstipationGastrointestinal disorders | 0/17 | 2/17 |
| PneumoniaRenal and urinary disorders | 2/17 | 2/17 |
| Ischaemic hepatitisHepatobiliary disorders | 0/17 | 1/17 |
| BacteraemiaInfections and infestations | 0/17 | 1/17 |
| DiverticulitisGastrointestinal disorders | 1/17 | 0/17 |
| PneumomediastinumRespiratory, thoracic and mediastinal disorders | 0/17 | 1/17 |
| ShockVascular disorders | 0/17 | 1/17 |
| Event | MN-166 (Ibudilast) | Placebo |
|---|---|---|
| BradycardiaCardiac disorders | 7/17 | 3/17 |
| Transaminases increasedInvestigations | 1/17 | 4/17 |
| LeukocytosisBlood and lymphatic system disorders | 0/17 | 3/17 |
| HyperglycaemiaEndocrine disorders | 0/17 | 3/17 |
| DiarrhoeaGastrointestinal disorders | 3/17 | 2/17 |
| Sinus bradycardiaCardiac disorders | 2/17 | 1/17 |
| HeadacheNervous system disorders | 1/17 | 2/17 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/17 | 2/17 |
| HypotensionVascular disorders | 0/17 | 2/17 |
| EosinophiliaBlood and lymphatic system disorders | 1/17 | 0/17 |
| Age, Continuous(years) | Ibudilast (MN-166) | Placebo | Total |
|---|---|---|---|
| Mean | 58.71 ± 11.32 | 61.06 ± 12.16 | 59.88 ± 11.63 |
| Sex: Female, Male(Participants) | Ibudilast (MN-166) | Placebo | Total |
|---|---|---|---|
| Female | 9 | 8 | 17 |
| Male | 8 | 9 | 17 |
| Ethnicity (NIH/OMB)(Participants) | Ibudilast (MN-166) | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 3 | 10 |
| Not Hispanic or Latino | 10 | 14 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Ibudilast (MN-166) | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 1 | 2 | 3 |
| White | 10 | 13 | 23 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 2 | 7 |
| Region of Enrollment(Participants) | Ibudilast (MN-166) | Placebo | Total |
|---|---|---|---|
| United States | 17 | 17 | 34 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2021 to primary completion in Jun 2022, 17 months.
Results were first posted in Oct 2024, 2 years 4 months after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 17 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibudilast
MediciNova